NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
Status:
Completed
Trial end date:
2018-07-19
Target enrollment:
Participant gender:
Summary
RATIONALE: Giving low doses of chemotherapy before a donor peripheral blood stem cell
transplant helps stop the growth of cancer cells. It also stops the patient's immune system
from rejecting the donor's stem cells. The donated stem cells may replace the patient's
immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving
an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help
increase this effect. Sometimes the transplanted cells from a donor can also make an immune
response against the body's normal cells. Giving immunosuppressive therapy before or after
the transplant may stop this from happening.
PURPOSE: This phase II trial is studying how well chemotherapy followed by donor peripheral
stem cell transplant works in treating patients with hematologic cancer or aplastic anemia.